Toxic amyloid-β protein (Aβ) conformers play an important role in the progression of Alzheimer’s disease (AD). The ratio of toxic conformer to total Aβ42 in cerebrospinal fluid (CSF) was significantly high in AD and mild cognitive impairment (MCI) due to AD using an enzyme-linked immunosorbent assay kit with a 24B3 antibody.
Objective:
We compared the toxic Aβ42, conformer at different stages of AD to identify its contribution to AD pathogenesis.
Methods:
We compared 5 patients with preclinical AD, 11 patients with MCI due to AD, 21 patients with AD, and 5 healthy controls to measure CSF levels of total Aβ42, total tau, tau phosphorylated at threonine 181 (p-tau), and toxic Aβ conformers. All were classified using the Clinical Dementia Rating. Cognitive function was assessed using the Japanese version of the Mini-Mental State Examination (MMSE-J).
Results:
Toxic Aβ conformer level was insignificant between groups, but its ratio to Aβ42 was significantly higher in AD than in preclinical AD (p < 0.05). Toxic Aβ42 conformer correlated positively with p-tau (r = 0.67, p < 0.01) and p-tau correlated negatively with MMSE-J (r = –0.38, p < 0.05).
Conclusion:
Toxic Aβ conformer triggers tau accumulation leading to neuronal impairment in AD pathogenesis.
OnoK (2018) Alzheimer’s disease as oligomeropathy. Neurochem Int119, 57–70.
5.
MurakamiK, TokudaM, SuzukiT, IrieY, HanakiM, IzuoN, MonobeY, AkagiK, IshiiR, TatebeH, TokudaT, MaedaM, KumeT, ShimizuT, IrieK (2016) Monoclonal antibody with conformational specificity for a toxic conformer of amyloid β42 and its application toward the Alzheimer’s disease diagnosis. Sci Rep6, 29038.
6.
AkibaC, NakajimaM, MiyajimaM, OginoI, MotoiY, KawamuraK, AdachiS, KondoA, SuganoH, TokudaT, IrieK, AraiH (2018) Change of amyloid-β 1-42 toxic conformer ratio after cerebrospinal fluid diversion predicts long-term cognitive outcome in patients with idiopathic normal pressure hydrocephalus. J Alzheimers Dis63, 989–1002.
7.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
8.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
9.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCRJr, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology43, 2412–2414.
12.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
13.
SugishitaM, HemmiI, TakeuchiT (2016) Reexamination of the validity and reliability of the Japanese version of the Mini-Mental State Examination (MMSE-J). Jpn J Cogn Neurosci18, 168–183.
14.
IrieK (2020) New diagnostic method for Alzheimer’s disease based on the toxic conformation theory of amyloid β. Biosci Biotechnol Biochem84, 1–16.
15.
MurakamiK, YamaguchiT, IzuoN, KumeT, HaraH, IrieK (2020) Synthetic and biophysical studies on the toxic conformer in amyloid β with the E22Δ mutation in Alzheimer pathology. ACS Chem Neurosci11, 3017–3024.
16.
TomiyamaT, NagataT, ShimadaH, TeraokaR, FukushimaA, KanemitsuH, TakumaH, KuwanoR, ImagawaM, AtakaS, WadaY, YoshiokaE, NishizakiT, WatanabeY, MoriH (2008) A new amyloid β variant favoring oligomerization in Alzheimer’s-type dementia. Ann Neurol63, 377–387.
17.
TomiyamaT, MatsuyamaS, IsoH, UmedaT, TakumaH, OhnishiK, IshibashiK, TeraokaR, SakamaN, YamashitaT, NishitsujiK, ItoK, ShimadaH, LambertMP, KleinWL, MoriH (2010) A mouse model of amyloid β oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci30, 4845–4856.
18.
MasudaY, IrieK, MurakamiK, OhigashiH, OhashiR, TakegoshiK, ShimizuT, ShirasawaT (2005) Verification of the turn at positions 22 and 23 of the β-amyloid fibrils with Italian mutation using solid-state NMR. Bioorg Med Chem13, 6803–6809.
19.
MasudaY, UemuraS, OhashiR, NakanishiA, TakegoshiK, ShimizuT, ShirasawaT, IrieK (2009) Identification of physiological and toxic conformations in Aβ42 aggregates. ChemBioChem10, 287–295.
20.
UmedaT, MaekawaS, KimuraT, TakashimaA, TomiyamaT, MoriH (2014) Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice. Acta Neuropathol127, 685–698.
21.
IzuoN, KasaharaC, MurakamiK, KumeT, MaedaM, IrieK, YokoteK, ShimizuT (2017) A toxic conformer of Aβ42 with a turn at 22-23 is a novel therapeutic target for Alzheimer’s disease. Sci Rep7, 11811.
De FeliceFG, WuD, LambertMP, FernandezSJ, VelascoPT, LacorPN, BigioEH, JerecicJ, ActonPJ, ShughruePJ, Chen-DodsonE, KinneyGG, KleinWL (2008) Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers. Neurobiol Aging29, 1334–1347.
24.
JinM, ShepardsonN, YangT, ChenG, WalshD, SelkoeDJ (2011) Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A108, 5819–5824.
25.
ImamuraT, YanagiharaYT, OhyagiY, NakamuraN, IinumaKM, YamasakiR, AsaiH, MaedaM, MurakamiK, IrieK, KiraJI (2020) Insulin deficiency promotes formation of toxic amyloid-β42 conformer co-aggregating with hyper-phosphorylated tau oligomer in an Alzheimer’s disease model. Neurobiol Dis137, 104739.
26.
Mattsson-CarlgrenN, AnderssonE, JanelidzeS, OssenkoppeleR, InselP, StrandbergO, ZetterbergH, RosenHJ, RabinoviciG, ChaiX, BlennowK, DageJL, StomrudE, SmithR, PalmqvistS, HanssonO (2020) Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease. Sci Adv6, eaaz2387.
27.
OnoK, TakahashiR, IkedaT, YamadaM (2012) Cross-seeding effects of amyloid β-protein and α-synuclein. J Neurochem122, 883–890.
28.
CoughlinDG, XieSX, LiangM, WilliamsA, PetersonC, WeintraubD, McMillanCT, WolkDA, AkhtarRS, HurtigH, CoslettHB, HamiltonR, SiderowfA, DudaJE, RascovskyK, LeeEB, LeeVMY, GrossmanM, TrojanowskiJQ, IrwinDJ (2019) Cognitive and pathological influences of tau pathology in Lewy body disorders. Ann Neurol85, 259–271.
29.
IrwinDJ, GrossmanM, WeintraubD, HurtigHI, DudaJE, XieSX, LeeEB, Van DeerlinVM, LopezOL, KoflerJK, NelsonPT, JichaGA, WoltjerR, QuinnJF, KayeJ, LeverenzJB, TsuangD, LongfellowK, YearoutD, KukullW, KeeneCD, MontineTJ, ZabetianCP, TrojanowskiJQ (2017) Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: A retrospective analysis. Lancet Neurol16, 55–65.
